131.14

0.19% 0.25

After Hours: 131.00 -0.14 -0.11%

Novo Nordisk Adr (NVO)

Overview News Price History Option Chain Why NVO Down? Discussions Forecast Stock Split Dividend History

Novo Nordisk Adr stock is traded at $131.14, with a volume of 2.59M. It is up +0.19% in the last 24 hours and up +0.78% over the past month. With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Previous Close:

$130.89

Open:

$133.76

24h Volume:

2.59M

Relative Volume:

0.69

Market Cap:

$583.84B

Revenue:

$37.42B

Net Income/Loss:

$13.05B

P/E Ratio:

54.47

EPS:

2.4077

Net Cash Flow:

$9.51B

1W Performance:

-5.76%

1M Performance:

+0.78%

6M Performance:

+5.12%

1Y Performance:

-31.43%

1-Day Range:

$130.57

$134.16

1-Week Range:

$130.53

$138.62

52-Week Range:

$86.96

$201.76

Novo Nordisk Adr Stock (NVO) Company Profile

Name

Novo Nordisk Adr

Sector

Healthcare (1181)

Industry

Biotechnology (669)

Phone

Address

Employee

69,260

Twitter

@novonordisk

Next Earnings Date

2024-08-07

Latest SEC Filings

NVO's Discussions on Twitter

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-30-24	Initiated	Goldman	Buy
Apr-12-24	Initiated	BMO Capital Markets	Outperform
Jan-23-24	Initiated	Morgan Stanley	Overweight
Jan-16-24	Resumed	UBS	Neutral
Dec-01-23	Initiated	Cantor Fitzgerald	Overweight
Oct-02-23	Initiated	Argus	Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-15-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-28-22	Downgrade	UBS	Neutral → Sell
Jun-27-22	Upgrade	Exane BNP Paribas	Underperform → Neutral
Jun-07-22	Upgrade	JP Morgan	Neutral → Overweight
May-31-22	Upgrade	Guggenheim	Neutral → Buy
Apr-25-22	Upgrade	Cowen	Market Perform → Outperform
Apr-12-22	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Mar-16-22	Upgrade	Deutsche Bank	Hold → Buy
Jan-25-22	Downgrade	Liberum	Hold → Sell
Dec-20-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-17-21	Downgrade	Deutsche Bank	Buy → Hold
Jan-20-21	Downgrade	Credit Suisse	Outperform → Neutral
Jan-15-21	Initiated	Deutsche Bank	Buy
Sep-29-20	Initiated	Berenberg	Hold
Jul-06-20	Downgrade	BofA Securities	Buy → Neutral
May-11-20	Downgrade	UBS	Buy → Neutral
May-04-20	Initiated	Cowen	Market Perform
Mar-16-20	Upgrade	BofA/Merrill	Neutral → Buy
Jan-03-20	Downgrade	Guggenheim	Buy → Neutral
Nov-18-19	Upgrade	Barclays	Equal Weight → Overweight
Sep-17-19	Upgrade	Citigroup	Neutral → Buy
Aug-30-19	Downgrade	Jefferies	Hold → Underperform
Jun-20-19	Downgrade	Deutsche Bank	Buy → Hold
Jun-11-19	Upgrade	Barclays	Underweight → Equal Weight
Apr-29-19	Upgrade	Credit Suisse	Neutral → Outperform
Jan-29-19	Initiated	Exane BNP Paribas	Outperform
Dec-11-18	Resumed	Jefferies	Hold
Oct-09-18	Initiated	Guggenheim	Buy
Dec-29-17	Upgrade	JP Morgan	Underweight → Neutral
Dec-06-17	Upgrade	BofA/Merrill	Neutral → Buy
Dec-01-17	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-25-17	Downgrade	Exane BNP Paribas	Outperform → Neutral
Sep-06-17	Upgrade	BofA/Merrill	Underperform → Neutral

View All

Novo Nordisk Adr Stock (NVO) Latest News

Sep 08, 2024

This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth. - The Motley Fool

Sep 08, 2024

Sep 07, 2024

Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead? - The Motley Fool

Sep 07, 2024

Sep 06, 2024